| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| BUY | BUY | SELL | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 550.55▲ | 546.26▲ | 541.48▲ | 559.99▼ | 563.46▼ |
| MA10 | 548.30▲ | 539.79▲ | 550.03▲ | 551.27▼ | 574.31▼ |
| MA20 | 546.77▲ | 549.69▲ | 554.96▼ | 565.63▼ | 588.13▼ |
| MA50 | 537.17▲ | 556.41▼ | 553.79▼ | 581.95▼ | 583.10▼ |
| MA100 | 547.76▲ | 552.63▼ | 560.84▼ | 595.38▼ | 505.92▲ |
| MA200 | 553.96▼ | 562.62▼ | 570.74▼ | 594.10▼ | 428.99▲ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.226▲ | 0.649▲ | -1.473▼ | 0.126▲ | -7.188▼ |
| RSI | 63.309▲ | 51.341▲ | 47.832▼ | 42.965▼ | 44.363▼ |
| STOCH | 90.509▲ | 71.166 | 49.229 | 50.191 | 30.732 |
| WILL %R | -4.734▲ | -21.546▲ | -25.768 | -49.401 | -73.060 |
| CCI | 87.694 | 32.803 | -21.809 | -93.623 | -128.821▼ |
|
Monday, June 30, 2025 10:13 AM
FDA raised safety concerns for Vyvgart Hytrulo in CIDP, while Argenx moves ARGX-119 into late-stage trials for rare neuromuscular disease.
|
|
Monday, June 30, 2025 09:30 AM
The FDA published a report highlighting a "severe worsening of chronic inflammatory demyelinating polyradiculoneuropathy" as a potential signal of serious risk with Vyvgart Hytrulo (efgartigimod alfa ...
|
|
Monday, June 30, 2025 09:09 AM
(NASDAQ:ARGX) is down ~7% in Monday trading after the U.S. FDA issued an alert on a potential signal of serious risks associated with Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase). The agency ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 30/06/25 | 558.11 | 562.10 | 511.465 | 551.19 | 1,428,793 |
| 27/06/25 | 559.745 | 565.2317 | 555.63 | 560.14 | 461,687 |
| 26/06/25 | 561.81 | 562.00 | 556.76 | 560.04 | 276,400 |
| 25/06/25 | 560.06 | 564.28 | 556.92 | 560.53 | 227,200 |
| 24/06/25 | 549.58 | 574.64 | 548.96 | 568.06 | 385,900 |
| 23/06/25 | 543.39 | 545.01 | 534.227 | 540.76 | 405,300 |
| 20/06/25 | 542.49 | 546.91 | 538.59 | 542.15 | 372,900 |
| 18/06/25 | 542.10 | 546.76 | 537.75 | 537.92 | 252,900 |
| 17/06/25 | 546.97 | 550.39 | 540.37 | 540.71 | 479,400 |
| 16/06/25 | 573.05 | 574.50 | 550.91 | 551.22 | 426,900 |
|
|
||||
|
|
||||
|
|